Other · developed by ASTRAZENECA
AZD3427 is a drug given by subcutaneous injection every two weeks in a clinical study in pulmonary hypertension (WHO Group 2) and heart failure.
Summary written with AI from the sources listed at the end of this page.
Heart FailurePulmonary Hypertension (World Health Organization Group 2)
Updated Nov 1, 2026. Something wrong or missing? Report it on the AZN page.
See AZN's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
AZN catalysts and pipeline →